DiJia Dynamic

On June 16, the Shandong Provincial Department of Industry and Information Technology issued the ''Announcement on the List of Specialized and Special New Small and Medium-sized Enterprises in Shandong Province in 2022 ''. Dijia Pharmaceutical Group relied on its product research and development and innovation advantages in the field of pharmaceutical raw materials and pharmaceutical intermediates. Selected in Shandong Province in 2022

From May 17 to 19, Degas Group welcomed the two-stage audit of the five-person group of environmental management system certification experts. The audit team gave unanimous praise to the establishment and operation of the company's environmental protection facilities and the environmental protection management on site, and successfully passed the two-stage audit of the system.

On May 30, on the occasion of the National Science and Technology Workers Day, the 8th Weihai Youth Science and Technology Award Ceremony was held. Comrade Song Huadong, Secretary of the Party Group and Chairman of the Municipal Association for Science and Technology, presided over the meeting. Lin Qiang, member of the Standing Committee of the Municipal Party Committee and Executive Deputy Mayor, attended the ceremony And speak

Dijia Pharmaceutical Group Co., Ltd. is a subsidiary of Disha Pharmaceutical Group and a national high-tech enterprise. Relying on the strong scientific research strength of Disha Pharmaceutical Group, the company has a professional research institute to provide the company with product development, process optimization and other technical services, scientific and technological research and

People do not stand without faith, and enterprises do not prosper without faith. In order to better promote the construction of corporate credit, under the guidance of the Bureau of Industry and Information Technology of Wendeng District, Weihai City, Shandong Province and the Management Committee of Wendeng Economic Development Zone, Dijia Pharmaceutical Group Co., Ltd. has established a credit leading group, credit council and other leaders.

On August 5, 2021, Dijia Pharmaceutical Group held a kick-off meeting for the Lean Operation Management System Project (Phase II). Wang Danqi, General Manager of Dijia Pharmaceutical Group, Jiang Lei, Production Director, and Yang Yu, Director of Superior Consulting, attended the meeting.

The out-of-control outbreak in India has caused global concern. As a major exporter of APIs in the world, the supply pattern of China and India has been affected. At the same time, with the emergence of a new wave of global trade protectionism, countries due to the epidemic on the pharmaceutical industry chain security demand increased, China's raw materials.

On June 22, 2021, Dijia Pharmaceutical Group held a closing meeting of the Lean Operation Management System Project (Phase I). Wang Danqi, General Manager of Dijia Pharmaceutical Group, Jiang Lei, Director of Production, Jiang Ying, Director of Superior Consulting Project, and Guo Yan, Director of Superior Consulting Business, attended the meeting.

On November 2, Dijia Pharmaceutical Group held a kick-off meeting of the Lean Operation Management System Project (Phase I). Wang Danqi, General Manager of Dijia Pharmaceutical Group, Jin Ning, Deputy General Manager, Zhang Zuofang, Deputy General Manager, and Jiang Ying, General Manager of Superior Consulting, attended the meeting. Wang Danqi, General Manager of Dijia

With the increasingly strict investigation and punishment of API monopoly by the state, will the huge amount of API monopoly cases involving subsidiaries make the future of Teyi Pharmaceutical Group Co., Ltd. (hereinafter referred to as Teyi Pharmaceutical, 002728.SZ) encounter a chain reaction? November 10,